Jaguar Animal Health, Inc. (NASDAQ:JAGX) Sees Significant Growth in Short Interest

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totaling 245,697 shares, an increase of 227.7% from the November 30th total of 74,987 shares. Approximately 7.1% of the shares of the company are sold short. Based on an average daily trading volume, of 566,481 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily trading volume, of 566,481 shares, the days-to-cover ratio is currently 0.4 days. Approximately 7.1% of the shares of the company are sold short.

Jaguar Animal Health Price Performance

Shares of Jaguar Animal Health stock opened at $1.09 on Friday. The company has a market capitalization of $4.07 million, a price-to-earnings ratio of -0.03 and a beta of -0.12. Jaguar Animal Health has a 52 week low of $1.00 and a 52 week high of $33.25. The stock’s 50-day simple moving average is $1.50 and its 200-day simple moving average is $2.00. The company has a quick ratio of 0.52, a current ratio of 0.81 and a debt-to-equity ratio of 4.08.

Jaguar Animal Health (NASDAQ:JAGX) last posted its earnings results on Friday, November 14th. The biotechnology company reported ($6.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.08) by ($1.20). Jaguar Animal Health had a negative net margin of 341.90% and a negative return on equity of 1,194.94%. The firm had revenue of $3.08 million during the quarter, compared to analyst estimates of $3.73 million. As a group, analysts expect that Jaguar Animal Health will post -0.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Jaguar Animal Health currently has an average rating of “Hold” and a consensus price target of $60.00.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.